Vaccination Against SARS-CoV-2 for Myeloma Patients: Do We Need a Booster Dose and How Frequent?
Patients with multiple myeloma (MM) are at increased risk for severe COVID-19 disease, hospitalization and death. In this context, it is essential to maintain an adequate immune profile. A third (first booster) dose has been offered with priority to patients with MM due to their immunocompromised st...
Main Author: | Evangelos Terpos |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-10-01
|
Series: | Hematology, Transfusion and Cell Therapy |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137922013153 |
Similar Items
-
SARS-CoV-2 Vaccines in Patients With Multiple Myeloma
by: Maria Gavriatopoulou, et al.
Published: (2021-03-01) -
Effectiveness of Booster Doses of the SARS-CoV-2 Inactivated Vaccine KCONVAC against the Mutant Strains
by: Chanchan Xiao, et al.
Published: (2022-09-01) -
Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2
by: Shashidhar Jaggaiahgari, et al.
Published: (2022-12-01) -
Vaccine breakthrough infections with SARS-CoV-2: Why older adults need booster vaccinations
by: Maria I. Ventura, et al.
Published: (2022-12-01) -
SARS-CoV-2 Variants and Vaccine Boosters
by: Rajeev Gupta
Published: (2023-07-01)